Chronic liver diseases due to infection with genoetype1/serotype 1 hepatitis C virus
Conditions
Interventions
Viekirax, once per day, 2 tablets per once (Paritaprevir 150mg,Ombitasvir 25mg, ritonavir 100mg), for 12 weeks
Sponsors
Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with chronic hapatitis or compensated liver cirrhosis due to HCV infection, and treated by Viekirax 2) HCV is genotype1 or serotype 1
Exclusion criteria
Exclusion criteria: 1)Patiens who have had allergy to any ingredients of Viekirax 2)Patienes who are taking any medicines which are on the lists of contraindication for coadministration in the pharmaceutical reference of Viekirax 3)Patients who show moderate-severe hepatic dysfunction (Child-Pugh classification B or C) 4)Patients who have been treated for hepatoma within 6 months before taking Viekrax
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This is an exploratory study to investigate whether 2D therapy with PTV/r/OBV restores host immune response against HCV via comparing changes in gene expression profiles between patients who achieve SVR vs. patients who do not achieve SVR. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)To further explore changes in immune response via analyzing the effect on cytokine changes in peripheral blood and analyzing effect at the molecular level 2)Predicion of hepatoma by using age, sex, fibrotic markers (APRI, FIB-4, and Fibro test etc.), fibrotic scoring, and cellular immunity 3)To explore host or viral factors contributing to SVR | — |
Countries
Japan
Contacts
Public ContactTetsuro Shimakami
Kanazawa University Hospital Department of Gastroenterology
Outcome results
None listed